Navigation Links
Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
Date:3/1/2013

SAN FRANCISCO, March 1, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Medical Officer, Dr. Robert Medve , is scheduled to present at the 33rd Annual Cowen and Company Healthcare Conference at the Boston Marriott Copley Place on Tuesday, March 5, 2013 at 8:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until April 8, 2013.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 clinical development as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. In the proprietary pipeline, NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Nov. 22, 2014  Sprout Pharmaceuticals today announced positive preliminary ... women treated with flibanserin up to 200 mg at bedtime ... presented at the 20 th Annual Fall Scientific Meeting ... in Miami . ... the Complete Response Letter and the Formal Dispute Resolution that ...
(Date:11/22/2014)... -- New data demonstrates that flibanserin, a novel, non-hormonal medicine ... sexual dysfunction, Hypoactive Sexual Desire Disorder (HSDD), does not ... women when taken at bedtime. The data was presented ... America,s (SMSNA) 20th Annual Fall Scientific Meeting ... SMSNA accepted this study as a late breaking abstract ...
(Date:11/22/2014)... MONMOUTH JUNCTION, N.J. , Nov. 21, 2014 ... immunotherapy company commercializing its European Union approved CytoSorb® ... countries worldwide, was awarded the Beacon of Light ... Annual Awards Celebration.  Dr. ... stated, "It is an honor to be recognized ...
Breaking Medicine Technology:Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... Inc. is pleased,to announce the dosing of the first ... study of AEG35156, a second generation antisense,therapeutic targeting XIAP, ... The study, made possible, in part, by funding ... 1-2, Multicenter, Open-Label Study,of the X- Linked Inhibitor of ...
... July 30 Anpath Group, Inc.,(OTC Bulletin Board: ... Inc. (ESI) announced that its EnviroTru(R),disinfectant has been ... Services (DMS) in the State of Florida. The ... LLC(TM) ( http://www.aworldofgreen.com ),worked with the ...
Cached Medicine Technology:Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156 2Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156 3Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 3
(Date:11/22/2014)... November 23, 2014 A classic black prom ... the most famous dress suppliers, has unveiled its new items ... dresses are now offered at a big discount, up to ... offer. , The new black prom dresses, made with ... to meet the needs of all customers, the company provides ...
(Date:11/22/2014)... Recently, Locks-Magnetic.com , one of ... promotion of mag locks for glass doors online. In ... on these fresh products. Customers can get more information ... doors are in excellent performance. Customers who want to ... soon as possible. They also can enjoy the ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 BambooFlooringChina.com ... the company has proudly released its new collection of ... discounted rates, up to 29% off. , According ... and sturdy tree-like grass, making it a highly renewable resource. ... products have a mixing color which comes from natural bamboo ...
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand ... wedding dresses; the business offers a wide range of ... ladies worldwide, allowing them to create multiple looks easily. ... this new collection of chic wedding dresses has been ... offered at discounted rates now. Dylan Queen can always ...
(Date:11/22/2014)... 22, 2014 Setria® Glutathione is ... approved it for use “as a therapeutically active ... within the Therapeutic Goods (Listing) Notice 2014 (No. ... Hakko’s Setria® Glutathione will be exclusivity distributed in ... sources and imports fine chemicals to Australian manufacturers. ...
Breaking Medicine News(10 mins):Health News:New Black Prom Dresses from BellasDress.com 2Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... to consider risks of hormone treatment, inform patients ... used class of prostate cancer drugs called gonadotropin-releasing hormone ... stroke and sudden death in men, a U.S. Food ... initial findings from a preliminary and ongoing analysis of ...
... 3 May 2010 [Vienna, Austria] Organizers of the XVIII ... Clinton, founder of the William J. Clinton Foundation and 42nd ... Aaron Motsoaledi will be among 19 high-level speakers who will ... AIDS 2010 will take place from 18 to 23 July ...
... will save lives this summer, if everything goes as planned ... been turned, so to speak, into a rudimentary centrifuge that ... without electricity. Rice sophomore Lila Kerr and freshman ... two months this summer as part of Beyond Traditional Borders ...
... Knowing your children,s friends and good communication are key, ... Parents can play an important role in preventing their ... and getting to know their friends, a new study ... with their children could have a substantial impact on ...
... cancers are four times more likely to develop Post-Traumatic ... Childhood Cancer Survivors Study has found. The study ... were diagnosed with cancer between 1970 and 1986 and ... study found that 589 survivors, or 9 percent, reported ...
... An in vivo study shows for the first time ... that mirrors the signaling pathways of the body,s fight ... system of the inner ear that sets baseline hearing ... "Our research shows, for the first time, that the ...
Cached Medicine News:Health News:FDA Reviews Side Effects From Prostate Cancer Therapy 2Health News:President Bill Clinton and South African Health Minister Aaron Motsoaledi to join 25,000 scientists, people living with HIV, and other stakeholders at XVIII International AIDS Conference in Vienna 2Health News:President Bill Clinton and South African Health Minister Aaron Motsoaledi to join 25,000 scientists, people living with HIV, and other stakeholders at XVIII International AIDS Conference in Vienna 3Health News:President Bill Clinton and South African Health Minister Aaron Motsoaledi to join 25,000 scientists, people living with HIV, and other stakeholders at XVIII International AIDS Conference in Vienna 4Health News:Revolution with a salad spinner 2Health News:Involved Parents Less Likely to Raise Bullies 2Health News:Survivors of childhood cancers 4 times more likely to develop post-traumatic stress disorder 2Health News:Survivors of childhood cancers 4 times more likely to develop post-traumatic stress disorder 3Health News:A stress-response system in the ear protects against hearing loss 2Health News:A stress-response system in the ear protects against hearing loss 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: